Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H15NO2 |
| Molecular Weight | 180.2323 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N[11CH3])[C@H](O)C1=CC=CC(O)=C1
InChI
InChIKey=KEEFJRKWMCQJLN-CGGDJVLNSA-N
InChI=1S/C10H15NO2/c1-7(11-2)10(13)8-4-3-5-9(12)6-8/h3-7,10-13H,1-2H3/t7-,10-/m0/s1/i2-1
| Molecular Formula | C10H15NO2 |
| Molecular Weight | 180.2323 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:33:53 GMT 2023
by
admin
on
Fri Dec 15 15:33:53 GMT 2023
|
| Record UNII |
VFB6950Q3Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
VFB6950Q3Y
Created by
admin on Fri Dec 15 15:33:53 GMT 2023 , Edited by admin on Fri Dec 15 15:33:53 GMT 2023
|
PRIMARY | |||
|
450145
Created by
admin on Fri Dec 15 15:33:53 GMT 2023 , Edited by admin on Fri Dec 15 15:33:53 GMT 2023
|
PRIMARY | |||
|
130440-31-2
Created by
admin on Fri Dec 15 15:33:53 GMT 2023 , Edited by admin on Fri Dec 15 15:33:53 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->RADIOLIGAND |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
DeGrado et al. (9) investigated the retention mechanisms of (11C)mHED (specific activity >55,500 GBq/mmol or >1500 Ci/mmol) and interactions with NE in isolated rat hearts. They found a strong uptake process (K1 = 2.66 +/- 0.39 ml/g/min n = 5) in the heart and a relatively slow clearance rate (k2 = 0.011 +/- 0.003 min1). NE appeared to increase the clearance rate (k2 = 0.016 +/- 0.009 min1 at 5 nM and 0.034 +/- 0.016 min1 at 10 nM) without affecting initial uptake rates (K1 = 2.81 +/- 0.25 ml/g/min at 5 nM and 2.53 +/- 0.67 ml/g/min at 10 nM). In the presence of 40 nM desipramine (DMI), a potent inhibitor of NET, (11C)mHED uptake was blocked. The study indicated that the uptake and retention of (11C)mHED by the heart was specific to sympathetic nerve terminals. Caldwell et al. (6) used isolated perfused rat hearts to demonstrated that an axially distributed blood-tissue exchange model could be used for the quantitation of cardiac presynaptic SNS function with (11C)mHED.
|
||
|
ACTIVE MOIETY |
RESULTS: In 14 patients with 19 pairs of examinations, the following tumors were confirmed histologically: 6 neuroblastomas, 5 pheochromocytomas, 1 ganglioneuroblastoma, and 2 paragangliomas. In 5 patients, each having 1 pair of examinations, clinical follow-up and/or histologic examination did not reveal any tumor deriving from the sympathetic nervous system. 11C-HED PET/CT detected 80 of 81 totally depicted tumor lesions (sensitivity, 0.99; soft tissue, 61; bone, 19). 123I-MIBG SPECT/CT detected 75 of 81 lesions (sensitivity, 0.93; soft tissue, 56; bone, 19). With both methods, there were no false-positive lesions. The tumor-to-background contrast of 11C-HED uptake was higher in comparison with 123I-MIBG uptake in 26 lesions (0.32; soft tissue, 18; bone, 8), equal in 39 lesions (0.48; soft tissue, 30; bone, 9), and lower than 123I-MIBG uptake in 16 lesions (0.20; soft tissue, 14; bone, 2).
CONCLUSION: Whole-body imaging using 11C-HED PET/CT is feasible in the clinical setting of patients with tumors of the sympathetic nervous system. 11C-HED PET/CT detected more tumor lesions than 123I-MIBG SPECT/CT. However, tumor-to-background contrast of 11C-HED in lesions can be higher, equal, or lower compared with 123I-MIBG.
|
